Document Detail

Repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: local control and survival results.
MedLine Citation:
PMID:  23127803     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate the local tumor control and survival data after transarterial chemoembolization with different drug combinations in the palliative treatment of patients with liver metastases of gastric cancer.
MATERIALS AND METHODS: The study was retrospectively performed. 56 patients (mean age, 52.4) with unresectable liver metastases of gastric cancer who did not respond to systemic chemotherapy were repeatedly treated with TACE in 4-week intervals. In total, 310 chemoembolization procedures were performed (mean, 5.5 sessions per patient). The local chemotherapy protocol consisted of mitomycin alone (30.4%), mitomycin and gemcitabine (33.9%), or mitomycin, gemcitabine and cisplatin (35.7%). Embolization was performed with lipiodol and starch microspheres. Local tumor response was evaluated by MRI according to RECIST. Survival data from first chemoembolization were calculated according to the Kaplan-Meier method.
RESULTS: The local tumor control was: complete response in 1.8% (n=1), partial response in 1.8% (n=1), stable disease in 51.8% (n=29) and progressive disease in 44.6% (n=25) of patients. The 1-, 2-, and 3-year survival rate from the start of chemoembolization were 58%, 38%, and 23% respectively. The median and mean survival times were 13 and 27.1 months. A Statistically significant difference between patients treated with different chemotherapy protocols was noted (ρ=0.045) with the best survival time in the mitomycin, gemcitabine and cisplatin group.
CONCLUSION: Transarterial chemoembolization is a minimally invasive therapy option for palliative treatment of liver metastases in patients with gastric cancer.
Thomas J Vogl; Tatjana Gruber-Rouh; Katrin Eichler; Nour-Eldin A Nour-Eldin; Jörg Trojan; Stephan Zangos; Nagy N N Naguib
Related Documents :
24096763 - Hepatic resection associated with good survival for selected patients with intermediate...
3631983 - Prognostic significance of hypopigmentation in malignant melanoma.
25395283 - Randomized, phase iii trial of figitumumab in combination with erlotinib versus erlotin...
Publication Detail:
Type:  Journal Article     Date:  2012-11-03
Journal Detail:
Title:  European journal of radiology     Volume:  82     ISSN:  1872-7727     ISO Abbreviation:  Eur J Radiol     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2012-12-31     Completed Date:  2013-07-09     Revised Date:  2013-09-24    
Medline Journal Info:
Nlm Unique ID:  8106411     Medline TA:  Eur J Radiol     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  258-63     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Institute for Diagnostic and Interventional Radiology, Johann Wolfgang Goethe-University Frankfurt, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Chemoembolization, Therapeutic / mortality*
Disease-Free Survival
Germany / epidemiology
Liver Neoplasms / mortality,  secondary*,  therapy*
Middle Aged
Neoplasm Recurrence, Local / mortality*,  prevention & control*
Retrospective Studies
Stomach Neoplasms / mortality*,  therapy*
Survival Analysis
Survival Rate
Treatment Outcome
Comment In:
Eur J Radiol. 2013 Sep;82(9):1592-4   [PMID:  23642764 ]
Eur J Radiol. 2013 Sep;82(9):1591-2   [PMID:  23642763 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Molecular cloning and characterization of the corticoid receptors from the American alligator.
Next Document:  Perfusion CT can predict tumoral grading of pancreatic adenocarcinoma.